Outcomes

The evidence for bremelanotide (PT-141) outcomes is primarily based on completed Phase 2 and Phase 3 clinical trials in premenopausal women with hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder, though detailed efficacy data from these trials is not available in the provided evidence.

Primary Clinical Applications:
Three completed clinical trials specifically evaluated bremelanotide in premenopausal women with HSDD, including two Phase 3 studies (NCT02338960, NCT02333071) and one Phase 2 study that also included women with female sexual arousal disorder (NCT01382719). However, the specific outcome measures, effect sizes, and statistical significance of results from these trials are not detailed in the available evidence.

Strength of Evidence:
The evidence base appears limited to completed clinical trials in female sexual dysfunction, with the provided literature focusing more on review articles and broader therapeutic considerations rather than presenting specific efficacy data. While multiple completed Phase 3 trials suggest regulatory-grade evidence exists, the actual measurable outcomes, biomarker changes, or symptom improvement metrics are not quantified in the available sources.

Emerging Applications:
Recent literature suggests potential consideration of bremelanotide for sexual arousal and desire disorders in men, though specific outcome data for this application is not provided in the evidence. The compound is also mentioned in the context of therapeutic peptides for aging-related conditions, but again without specific efficacy metrics.

Evidence Limitations:
The available evidence does not include published results from the completed clinical trials, making it impossible to report specific measurable outcomes, effect sizes, response rates, or biomarker changes. The strength of evidence for bremelanotide's clinical efficacy cannot be adequately assessed based solely on trial registry information and review articles without access to the primary efficacy data.

This summary is for informational purposes only and should not replace consultation with a healthcare provider for personalized medical advice.

Bremelanotide (PT-141)

Member access required